Innate Pharma (IPHYF) Receivables - Other (2017 - 2025)

Innate Pharma's Receivables - Other history spans 9 years, with the latest figure at $657684.6 for Q4 2025.

  • For Q4 2025, Receivables - Other rose 591.54% year-over-year to $657684.6; the TTM value through Dec 2025 reached $657684.6, up 591.54%, while the annual FY2025 figure was $657684.6, 582.75% up from the prior year.
  • Receivables - Other reached $657684.6 in Q4 2025 per IPHYF's latest filing, up from $95105.0 in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $931192.4 in Q4 2021 to a low of $62235.1 in Q4 2022.
  • Average Receivables - Other over 5 years is $371623.0, with a median of $111897.7 recorded in 2023.
  • Peak YoY movement for Receivables - Other: crashed 93.32% in 2022, then surged 591.54% in 2025.
  • A 5-year view of Receivables - Other shows it stood at $931192.4 in 2021, then plummeted by 93.32% to $62235.1 in 2022, then skyrocketed by 79.8% to $111897.7 in 2023, then dropped by 15.01% to $95105.0 in 2024, then soared by 591.54% to $657684.6 in 2025.
  • Per Business Quant, the three most recent readings for IPHYF's Receivables - Other are $657684.6 (Q4 2025), $95105.0 (Q4 2024), and $111897.7 (Q4 2023).